Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R C Bush

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Science (New York, N.Y.)|July 1, 1977
Stereopsis in the falconR Fox, S W Lehmkuhle, R C Bush
Atherosclerosis|November 1, 1989
Mechanism of antiatherogenic action of calcium antagonistsC L Jackson, R C Bush, D E Bowyer
Atherosclerosis|February 1, 1988
Inhibitory effect of calcium antagonists on balloon catheter-induced arterial smooth muscle cell proliferation and lesion sizeC L Jackson, R C Bush, D E Bowyer
Naunyn-Schmiedeberg'S Archives of Pharmacology|January 1, 1996
RPR 101821, a new potent cholesterol-lowering agent: inhibition of squalene synthase and 7-dehydrocholesterol reductaseD Amin, R Z Rutledge, S J Needle, et al.
Biochemical Pharmacology|October 25, 1996
Hypolipidaemic properties of a potent and bioavailable alkylsulphinyl-diphenylimidazole ACAT inhibitor (RP 73163) in animals fed diets low in cholesterolD Riddell, C P Bright, B J Burton, et al.
Journal of Medicinal Chemistry|November 13, 1992
Acyl-CoA:cholesterol O-acyl transferase (ACAT) inhibitors. 1. 2-(Alkylthio)-4,5-diphenyl-1H-imidazoles as potent inhibitors of ACATN V Harris, C Smith, M J Ashton, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 1, 1997
RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductaseD Amin, R Z Rutledge, S N Needle, et al.
Biochemical Pharmacology|February 23, 1996
RP 64477: a potent inhibitor of acyl-coenzyme A:cholesterol O-acyltransferase with low systemic bioavailabilityA A Bello, C Bright, B J Burton, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Science (New York, N.Y.)|July 1, 1977
Stereopsis in the falconR Fox, S W Lehmkuhle, R C Bush
Atherosclerosis|November 1, 1989
Mechanism of antiatherogenic action of calcium antagonistsC L Jackson, R C Bush, D E Bowyer
Atherosclerosis|February 1, 1988
Inhibitory effect of calcium antagonists on balloon catheter-induced arterial smooth muscle cell proliferation and lesion sizeC L Jackson, R C Bush, D E Bowyer
Naunyn-Schmiedeberg'S Archives of Pharmacology|January 1, 1996
RPR 101821, a new potent cholesterol-lowering agent: inhibition of squalene synthase and 7-dehydrocholesterol reductaseD Amin, R Z Rutledge, S J Needle, et al.
Biochemical Pharmacology|October 25, 1996
Hypolipidaemic properties of a potent and bioavailable alkylsulphinyl-diphenylimidazole ACAT inhibitor (RP 73163) in animals fed diets low in cholesterolD Riddell, C P Bright, B J Burton, et al.
Journal of Medicinal Chemistry|November 13, 1992
Acyl-CoA:cholesterol O-acyl transferase (ACAT) inhibitors. 1. 2-(Alkylthio)-4,5-diphenyl-1H-imidazoles as potent inhibitors of ACATN V Harris, C Smith, M J Ashton, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 1, 1997
RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductaseD Amin, R Z Rutledge, S N Needle, et al.
Biochemical Pharmacology|February 23, 1996
RP 64477: a potent inhibitor of acyl-coenzyme A:cholesterol O-acyltransferase with low systemic bioavailabilityA A Bello, C Bright, B J Burton, et al.
Pageof 1